Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11601 - 11625 of 12063 in total
LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer).
Investigational
Matched Description: … LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab …
Thymoquinone is a natural compound with widespread protective effects, including anti-oxidative, anti-inflammatory, immunomodulatory, anti-cancer, and anti-microbial.
Investigational
Matched Description: … Thymoquinone is a natural compound with widespread protective effects, including anti-oxidative, anti-inflammatory …
Torudokimab is under investigation in clinical trial NCT03831191 (A Study of LY3375880 in Adults With Moderate-to-severe Atopic Dermatitis).
Investigational
Matched Description: … Torudokimab is under investigation in clinical trial NCT03831191 (A Study of LY3375880 in Adults With …
DSP107 is a bi-functional, trimeric, fusion protein composed of sequences from the extracellular domain of SIRPα and 4-1BBL.
Investigational
Matched Description: … DSP107 is a bi-functional, trimeric, fusion protein composed of sequences from the extracellular domain …
SerpinPC is a mutated alpha-1-antitrypsin (α1AT) and serine protease inhibitor being investigated for the treatment of hemophilia.
Investigational
Matched Description: … SerpinPC is a mutated alpha-1-antitrypsin (α1AT) and serine protease inhibitor being investigated for …
PNT001 is a humanized IgG4 S228P monoclonal antibody targeting the cis conformation of the phosphorylated Thr231-Pro232 motif in tau.
Investigational
Matched Description: … PNT001 is a humanized IgG4 S228P monoclonal antibody targeting the cis conformation of the phosphorylated …
TRK-250 is a small interfering RNA agent that targets human transforming growth factor-beta 1 (TGF-β1) messenger RNA.
Investigational
Matched Description: … TRK-250 is a small interfering RNA agent that targets human transforming growth factor-beta 1 (TGF-β1 …
Tetraethylammonium is an experimental drug with no approved indication or marketed formulation. The only marketed drug containing tetraethylammonium was a combination drug called Fosglutamina B6, but this drug has now been discontinued. As an experimental agent, tetraethylammonium is used in its salt forms such as tetraethylammonium chloride and tetraethylammonium bromide....
Experimental
Investigational
Matched Description: … The only marketed drug containing tetraethylammonium was a combination drug called Fosglutamina B6, but ... The most common use of tetraethylammonium presently is as a pharmacological research agent that blocks ... Because of its inhibitory actions at the autonomic ganglia, tetraethylammonium was thought to be a potential …
Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of the oesophagus. It is developed by Cellerix and is in phase I of clinical trials.
Investigational
Matched Description: … Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction …
KB002 is an engineered human IgG1k antibody engineered human. It is developed for the treatment of autoimmune diseases, initially rheumatoid arthritis.
Investigational
Investigational
Mocetinostat has been used in trials studying the treatment of Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma, among others.
Investigational
VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.
Investigational
Matched Description: … VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia …
Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.
Experimental
Matched Description: … Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. …
Tandamine was researched in 1970s as an antidepressant but was never commercialized. Tandamine is an analog of pirandamine and it acts as a selective serotonin reuptake inhibitor (SSRI).
Experimental
Matched Description: … Tandamine is an analog of pirandamine and it acts as a selective serotonin reuptake inhibitor (SSRI). …
Hx 1171 is under investigation in clinical trial NCT01548391 (A Phase I Clinical Study Study of the Safety, Tolerability, and Pharmacokinetics of HX-1171 in Healthy Male Subjects).
Investigational
Matched Description: … Hx 1171 is under investigation in clinical trial NCT01548391 (A Phase I Clinical Study Study of the Safety …
PF-05089771 is under investigation in clinical trial NCT01529671 (A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee).
Investigational
Matched Description: … PF-05089771 is under investigation in clinical trial NCT01529671 (A Safety And Tolerability Study Of …
PCS-499 is under investigation in clinical trial NCT01487109 (A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients).
Investigational
Matched Description: … PCS-499 is under investigation in clinical trial NCT01487109 (A Phase 2 Study to Evaluate the Safety …
Human Lactoferrin Peptide hLF1-11 is under investigation in clinical trial NCT00509834 (A Study on the Tolerability and Early Efficacy of Hlf1-11 in Patients With Proven Candidaemia).
Investigational
Matched Description: … Human Lactoferrin Peptide hLF1-11 is under investigation in clinical trial NCT00509834 (A Study on the …
Zampilimab is under investigation in clinical trial NCT04335578 (A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of UCB7858 in Adult Kidney Transplant Recipients With Chronic Allograft Injury).
Investigational
Matched Description: … Zampilimab is under investigation in clinical trial NCT04335578 (A Study to Evaluate Safety, Tolerability …
Utidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue produced by genetic engineering.[A257544,A257549] It is under investigation in clinical trials for various cancers.
Investigational
Matched Description: … Utidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue produced by genetic …
Bacteroides thetaiotaomicron is a live biotherapeutic. Developed by 4D Pharma, Thetanix, an oral formulation comprising lyophilized Bacteroides thetaiotaomicron, is being investigated for the treatment of Crohn’s disease.
Investigational
Matched Description: … Bacteroides thetaiotaomicron is a live biotherapeutic. …
Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. The interferon is primarily produced by activated T lymphocytes and natural killer cells.
Investigational
Matched Description: … Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. …
R673 is a novel NK1 antagonist that penetrates the blood-brain barrier, has excellent safety and tolerability and shows low P450-based drug interaction potential. The phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but...
Investigational
Matched Description: … R673 is a novel NK1 antagonist that penetrates the blood-brain barrier, has excellent safety and tolerability …
GPX-100 is an anthracycline anticancer drug that belongs to the family of drugs called antitumor antibiotics.
Investigational
Displaying drugs 11601 - 11625 of 12063 in total